Cyclerion Therapeutics (CYCN) Liabilities and Shareholders Equity (2018 - 2025)

Cyclerion Therapeutics' Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $10.0 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity rose 4.28% year-over-year to $10.0 million; the TTM figure through Dec 2025 stood at $39.6 million (down 0.71% YoY), while the FY2025 annual figure was $10.0 million, up 4.28% from the prior year.
• Liabilities and Shareholders Equity was $10.0 million for Q4 2025 at Cyclerion Therapeutics, down from $10.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $100.0 million in Q1 2021 to a low of $8.9 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $27.9 million across 5 years, with a median of $12.4 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity tumbled 75.38% in 2023, then gained 17.05% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $59.3 million in 2021, then slumped by 69.53% to $18.1 million in 2022, then fell by 26.02% to $13.4 million in 2023, then decreased by 28.41% to $9.6 million in 2024, then climbed by 4.28% to $10.0 million in 2025.
• The last three Liabilities and Shareholders Equity figures came in at $10.0 million (Q4 2025), $10.4 million (Q3 2025), and $9.4 million (Q2 2025), per Business Quant data.